Discoveries in CAEL-101 Trial for Patients with AL Amyloidosis

episode

Cleveland Clinic Cancer Advances not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-22-2026 7PM EDT 4 min · 22 Sep 2026 · NPR News Now

H4 N2K, Shehan Jeyarajah, The Kicker 45 min · 22 Sep 2026 · The Program

US-Iran Talks on Sidelines of UN Summit, Chipmakers Rally, More 7 min · 22 Sep 2026 · Bloomberg News Now

7PM ET 09/22/2026 Newscast 3 min · 22 Sep 2026 · Fox News Hourly Update

Dentists Are Making Millions From This Lie - Dr. Ellie Phillips EXPOSES the dental industry 1h 5m · 22 Sep 2026 · Redacted News

Inside Big Brother: Nasty Nick (Ep 1) 39 min · 22 Sep 2026 · The Rest Is Entertainment

Report any issue

Source

Recorded12 May 2022

Publisherfeeds.buzzsprout.com

Handlerec:1648279

Show notes

Jason Valent, MD, Director of the Multiple Myeloma Program and Co-Director of the Amyloidosis Program at Cleveland Clinic Cancer Center, joins the Cancer Advances podcast to discuss the developments of the CAEL-101 trial for patients with AL amyloidosis. Listen as Dr. Valent talks about the discoveries and changes in treatment in each phase of the trial.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in